Maximilian Ehrenfeld

Mr. Maximilian Ehrenfeld

PhD candiate TUM
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Klaus MantwillKlaus Mantwill
Klaus Mantwill
FKFlorian Gerhard Klein
Florian Gerhard Klein
DWDongbiao Wang
Dongbiao Wang
SVSruthi Hindupur Vasantamadhava
Sruthi Hindupur Vasantamadhava
MEMaximilian Ehrenfeld
Maximilian Ehrenfeld
Roman NawrothRoman Nawroth
Roman Nawroth
Oncolytic adenovirus therapy is gaining importance as a novel treatment option for the management of various cancers. Different concepts of modification within the adenovirus vector have been identified that define the mode of action against and the interaction with the tumour. Adenoviral vectors allow for genetic manipulations that restrict tumour specificity and also the expression of specific transgenes in order to support the anti-tumour effect. Additionally, replication of the virus and reinfection of neighbouring tumour cells amplify the therapeutic effect. Another important aspect in oncolytic adenovirus therapy is the virus induced cell death which is a process that activates the immune system against the tumour. This review describes which elements in adenovirus vectors have been identified for modification not only to utilize oncolytic adenovirus vectors into conditionally replicating adenoviruses (CRAds) that allow replication specifically in tumour cells but also to confer specific characteristics to these viruses. These advances in development resulted in clinical trials that are summarized based on the conceptual design.

10 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JKJana Annika Koch
Jana Annika Koch
SSSebastian Schober
Sebastian Schober
SHSruthi V. Hindupur
Sruthi V. Hindupur
CSCaroline Schöning
Caroline Schöning
FKFlorian Gerhard Klein
Florian Gerhard Klein
PHPer Sonne Holm
Per Sonne Holm
CDK4/6 inhibitors (CDK4/6i) and oncolytic viruses are promising therapeutic agents for the treatment of various cancers. As single agents, CDK4/6 inhibitors that are approved for the treatment of breast cancer in combination with endocrine therapy cause G1 cell cycle arrest, whereas adenoviruses induce progression into S-phase in infected cells as an integral part of the their life cycle. Both CDK4/6 inhibitors and adenovirus replication target the Retinoblastoma protein albeit for different purposes. Here we show that in combination CDK4/6 inhibitors potentiate the anti-tumor effect of the oncolytic adenovirus XVir-N-31 in bladder cancer and murine Ewing sarcoma xenograft models. This increase in oncolytic potency correlates with an increase in virus-producing cancer cells, enhanced viral genome replication, particle formation and consequently cancer cell killing. The molecular mechanism that regulates this response is fundamentally based on the reduction of Retinoblastoma protein expression levels by CDK4/6 inhibitors.